Q32 Bio Raises $187.6M in Public Offering of Stock & Warrants

Q32 Bio Inc. has entered into an underwriting agreement for a public offering of common stock and pre-funded warrants. The offering includes 6,027,399 shares of common stock at $18.25 per share and pre-funded warrants to purchase up to 4,931,506 shares at $18.2499 per warrant. The company expects to raise approximately $187.6 million in net proceeds, potentially increasing to $215.8 million if the underwriters fully exercise their option for additional shares. The funds are intended for working capital, research, clinical development, and commercialization efforts, including advancing bempikibart into future clinical trials.